# Study of AZD2811 + Durvalumab in ES-SCLC

Source: https://onco.cc/trials/nct04745689/  
OnCo record `nct04745689` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Durvalumab, Carboplatin, Cisplatin in small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Study of AZD2811 + Durvalumab in ES-SCLC is a phase 2 interventional study registered as NCT04745689 by AstraZeneca, with 31 participants enrolled, started 2021-02-23 and due to reach its primary completion in 2022-06-18. Interventions recorded: Durvalumab, AZD2811, Carboplatin, Cisplatin, Etoposide. Conditions listed: Small-Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: TAZMAN
- Tags: ctgov-ingest
- Registry id: NCT04745689
- Phase: 2
- Setting: A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung Cancer
- Sponsor: AstraZeneca
- Enrolled: 31
- Outcomes: Overall Survival (OS) in Maintenance Participants: AZD2811 + Durvalumab 9.99 months

## Sources

- ClinicalTrials.gov NCT04745689: https://clinicaltrials.gov/study/NCT04745689

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Etoposide](https://onco.cc/drugs/etoposide/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct04745689.json